

Acceptability and preliminary efficacy of a novel webbased physical activity for the heart (PATH) intervention designed to promote physical activity in adults with obesity: Protocol for a pilot randomized controlled trial

Jacob Kariuki, Lora E. Burke, Kirk I. Erickson, Susan Sereika, Sudeshna Paul, Jessica Cheng, Heran Biza, Amjad Abdirahman, Katherine Wilbraham, Hether Milton, Cornelius Brown, Mathew Sells, Foster Osei Baah, Jessica Wells, Rasheeta Chandler, Bethany Gibbs

Submitted to: JMIR Research Protocols on: October 25, 2024

Disclaimer: © **The authors. All rights reserved.** This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.

Table of Contents

Original Manuscript	5
Supplementary Files	
Multimedia Appendixes	32
Multimedia Appendix 0	22

Acceptability and preliminary efficacy of a novel web-based physical activity for the heart (PATH) intervention designed to promote physical activity in adults with obesity: Protocol for a pilot randomized controlled trial

Jacob Kariuki¹ PhD; Lora E. Burke² PhD; Kirk I. Erickson³ PhD; Susan Sereika² PhD; Sudeshna Paul¹ PhD; Jessica Cheng⁴ PhD; Heran Biza¹ MS; Amjad Abdirahman¹ BS; Katherine Wilbraham¹ BS; Hether Milton⁵ MS; Cornelius Brown¹ BS; Mathew Sells¹ BS; Foster Osei Baah¹ PhD; Jessica Wells¹ PhD; Rasheeta Chandler¹ PhD; Bethany Gibbs⁶ PhD

Corresponding Author:

Jacob Kariuki PhD Emory University 1520 Clifton Rd Suite 244 Atlanta US

Abstract

Background: Even in the absence of weight-loss, any level of physical activity (PA) can reduce the risk of CVD among individuals with obesity. However, these individuals face multifaceted barriers that reduce their motivation and engagement in PA. They prefer programs that are convenient, fun to engage in, and feature people who they can relate to. Yet, there is a paucity of PA interventions that are designed to incorporate these preferences. We designed the web-based PA for The Heart (PATH) intervention to address this gap.

Objective: To describe the protocol of a study that aims to examine the acceptability and preliminary efficacy of PATH intervention among 88 insufficiently active adults with obesity aged at least 18 years old.

Methods: A 6-month pilot randomized controlled trial (RCT), using a parallel design with 1:1 allocation to intervention or control group. The PATH intervention group are given access to the PATH platform, but the resources each participant can access are tailored according to their baseline fitness level. Control group receive a self-help PA handout. Both group self-monitor their PA using Fitbit and have twice/month meetings with either the health coach (intervention) or study coordinator (control). The outcomes at 6-months include acceptability, changes in PA and cardiometabolic risk factors from baseline to 6-months.

Results: N/A

Conclusions: The PATH intervention offers a promising, evidence-based approach to overcoming the barriers that have hindered previous PA programs for adults with obesity. It can support new and existing program to foster long-term maintenance of health-enhancing PA. Clinical Trial: NCT05803304

(JMIR Preprints 25/10/2024:67972)

DOI: https://doi.org/10.2196/preprints.67972

Preprint Settings

¹Emory University Atlanta US

²University of Pittsburgh Pittsburgh US

³AdventHealth Research Institute, Neuroscience Orlando US

⁴Harvard University T. H. Chan School of Public Health, MA, USA and Massachusetts General Hospital Boston US

⁵NYU Langone Health New York US

⁶West Virginia University School of Public Health Morgantown US

- 1) Would you like to publish your submitted manuscript as preprint?
- **✓** Please make my preprint PDF available to anyone at any time (recommended).

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users. Only make the preprint title and abstract visible.

- No, I do not wish to publish my submitted manuscript as a preprint.
- 2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?
- ✓ Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain very Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in <a href="http://example.com/above/pat/46/2016/ed/2016/e

Original Manuscript

Acceptability and preliminary efficacy of a novel web-based physical activity for the heart (PATH) intervention designed to promote physical activity in adults with obesity: Protocol for a pilot randomized controlled trial

Jacob K. Kariuki, PhD¹, Lora E. Burke, PhD, MPH², Kirk I. Erickson, PhD³, Susan Sereika, PhD², Sudeshna Paul, PhD¹, Jessica Cheng, PhD⁴, Heran Biza, MS,¹ Amjad Abdirahman, BS¹, Katherine Wilbraham BS¹, Hether Milton, MS⁵, Cornelius Brown, BS¹, Matt Sells, BS¹, David Ogutu, BS⁶, Foster Osei Baah, PhD¹, Jessica Wells, PhD¹, Rasheeta Chandler PhD¹, Bethany Gibbs, PhD⁵

Corresponding author:

Jacob K. Kariuki

Emory University

1520 Clifton Rd, Atlanta, GA 30322

Office: (404) 727-7980

Email: Jacob.Kariuki@emory.edu

Disclosures

Conflict of Interest: none declared.

Abstract

Background: Even in the absence of weight-loss, any level of physical activity (PA) can reduce the risk of CVD among individuals with obesity. However, these individuals face multifaceted barriers

¹Emory University, GA, USA

²University of Pittsburgh, PA, USA

³AdventHealth Research Institute, Neuroscience, FL, USA

⁴Harvard University T. H. Chan School of Public Health, MA, USA & Massachusetts General Hospital, MA, USA

⁵ NYU Langone Health, NY, USA

⁶Ritiko Consulting, TN, USA

⁷West Virginia University School of Public Health, WV, USA

that reduce their motivation and engagement in PA. They prefer programs that are convenient, fun to engage in, and feature people who they can relate to. Yet, there is a paucity of PA interventions that are designed to incorporate these preferences. We designed the web-based <u>PA</u> for <u>The Heart (PATH)</u> intervention to address this gap.

Purpose: To describe the protocol of a study that aims to examine the acceptability and preliminary efficacy of PATH intervention among 88 insufficiently active adults with obesity aged at least 18 years old.

Methods: A 6-month pilot randomized controlled trial (RCT), using a parallel design with 1:1 allocation to intervention or control group. The PATH intervention group are given access to the PATH platform, but the resources each participant can access are tailored according to their baseline fitness level. Control group receive a self-help PA handout. Both group self-monitor their PA using Fitbit and have twice/month meetings with either the health coach (intervention) or study coordinator (control). The outcomes at 6-months include acceptability, changes in PA and cardiometabolic risk factors from baseline to 6-months.

Conclusions: The PATH intervention offers a promising, evidence-based approach to overcoming the barriers that have hindered previous PA programs for adults with obesity. It can support new and existing program to foster long-term maintenance of health-enhancing PA.

Background

Only about 14% of adults with obesity attain the minimum levels of physical activity (PA) recommended by public health guidelines to achieve health benefits.^{1–3} Low levels of PA contribute to the high population burden of cardiovascular disease (CVD) as they increase the relative risk of stroke, coronary heart disease, and diabetes by 60%, 45%, and 30%, respectively.^{4–6} Even in the

absence of weight-loss, regular PA can significantly reduce the risk of CVD among individuals with obesity.^{3,7,8} However, individuals face complex and multifaceted barriers that reduce their motivation and engagement in regular PA for meeting current recommendations.^{9,10}

Barriers to PA associated with obesity include stigma, shame, poor fitness, and low self-efficacy. These evoke fears of embarrassment and pain, contributing to aversion and avoidance of PA. ^{10–12} To mitigate these barriers, web-based PA programs targeting adults with obesity have been developed. Preliminary data suggest improved retention for virtual programs, but the effects on PA are heterogeneous. ¹³ Limitations of these interventions include absence of human contact, 'one-size-fits-all' strategies, unmet weight-loss expectations, and generic content that fails to address the barriers associated with obesity. ^{10,14} We, ¹⁵ and others, ^{9,10} have reported that individuals with obesity prefer programs that are convenient, fun to engage in, and feature people who they can relate to with respect to body size, fitness level, and age. Yet, there is a paucity of PA interventions that are web-based and intentionally designed to flexibly incorporate these preferences. ^{10,16,17}

To address the limitations of previous interventions, our research team designed the web-based PA for The Heart (PATH) intervention. PATH leverages openly accessible platforms, such as YouTube, to provide workout videos that match the specific preferences expressed in our formative studies and the extant literature. In developing PATH, we employed an iterative bottom-up approach where our target population was engaged in the selection and rating of the workout videos. Then, highly rated workouts (≥3.5/5 stars) were vetted by the study team for content relevance and safety, and then curated on our PATH website in 3 intensity levels (beginner, intermediate, proficient) to foster gradual progression from low- to high-intensity PA. We added backend features that enable a remote health coach to help users set their PA goals and select a PA regimen that is safe for their fitness level. Each PATH user has a personalized dashboard displaying their recommended workouts and progress towards their PA goals.

We have successfully beta-tested the PATH platform (N=25) and completed a 12-week feasibility study where we met our recruitment goal (N=82) and attained excellent retention (96%). Intervention engagement was high, and the PATH group significantly increased objective moderate-to-vigorous PA (MVPA) indicating preliminary efficacy. The feedback we obtained from this study included the need to provide resources that can help participants improve their diet, provide feedback on cardiometabolic health indicators, and the need to improve our machine learning algorithm designed to keep the PATH platform up to date.

We used this feedback to further refine the PATH platform by curating nutritional resources focusing on improving diet quality and added a user-facing dashboard with feedback on five measures of

cardiovascular health including physical activity, blood pressure, weight, heart rate and sleep efficiency. Also, we optimized the platform's machine learning algorithm (PATH Fresher) that continually identifies new workout videos that match those preferred by the PATH users to be used in future updates of the platform.

This paper describes the protocol of a 6-month pilot randomized controlled trial (RCT), using a parallel design with 1:1 allocation to intervention or control, and designed to assess the preliminary efficacy of the optimized PATH intervention for promoting adherence to PA guidelines among 88 insufficiently active adults with obesity. We hypothesized that participants who are randomized to the optimized PATH intervention will show greater increases in PA at 6 months compared to those assigned to the attention control group. We also hypothesized that the optimized PATH intervention group will have a more favorable cardiometabolic risk profile at 6 months compared to the attention control group.

Methods

Study design. This is a 6-month, ongoing parallel group RCT including 88 participants with insufficient activity and obesity who are randomized 1:1 to either the PATH intervention or an attention control group. The PATH intervention group are given access to the PATH platform, but the resources each participant can access are tailored according to their baseline fitness level (details described below under optimized PATH intervention). Additionally, the intervention group receive text/email reminders to log into PATH and do their workouts based on their preferred schedule and will have twice/month virtual meetings with fitness coaches to monitor progress and review PA goals. The control group receives the *Be Active Your Way* booklet which is as an evidence-based self-help resource for promoting PA¹⁹ and twice/monthly virtual meetings with the study coordinator to check-in on their progress in the study and maintain contact. The staff conducting the study assessments are blinded to randomized group allocation.

Setting. The study is conducted at Emory University, with participants recruited primarily from the Atlanta metro region. The Institutional Review Board approved the study protocol prior to beginning the study. A written informed consent is obtained from all participants prior to participation in study procedures.

Participants. Eligibility criteria include reliable access to the Internet, age ≥18 years, BMI ≥30 kg/m², successful self-monitoring of PA (≥4 days with ≥10 hours wear time) via a waist-worn Actigraph accelerometer during a run-in period, Table 1. The questionnaires and assessment schedule and classification as insufficiently active

according to the PA Guidelines (<150 min of MVPA/wk) based on self-reported PA from the

Behavioral Risk Factor Surveillance System PA questionnaire.²⁰ Exclusion criteria include pregnancy or intention to become pregnant within 6 months, mobility restrictions, use of implantable electronic medical devices, or any condition that requires supervised PA (e.g., stroke). Individuals with a history of heart disease, diabetes, or those who respond in the affirmative to any question in the Physical Activity Readiness Questionnaire (PARQ)²¹ are required to obtain medical clearance from a primary care provider.

Recruitment. To obtain our target

sample (N=88), we
leverage resources
available to Emory
investigators, including
Georgia Clinical and
Translational Science
Institute, ResearchMatch
(registry of research
volunteers), electronic
mailings, announcements
on social media sites, and
fliers posted in the
community. We are also
recruiting from primary
care practices affiliated
with Emory Healthcare,
with an aim to recruit a
diverse sample that
includes ≥25% males and
≥30% racial/ethnic
minorities.

Screening and online	
questionnaires.	

arget				
Questionnaires Baseline 6 mos	and	scheduled	assess	sments
Screening, Health History	y and Lifestyle	Questionnaires		
<u> </u>	-		Χ	
Sociodemographic and Medical History Questionnaires PA Readiness Questionnaire (PAR-Q+) ²¹		X		
			X	Χ
Paffenbarger Exercise Habits Questionnaire ²² Barriers Self Efficacy Scale ²³		X	X	
PROMIS SF Sleep D		uestionnaire ²⁴	X	X
•	_	ment Questionnaire ²⁴	X	X
		Depression Scale (CES-		X
D) ²⁵		b Depression Scale (CES-	Χ	X
NIH Toolbox Perceive			Χ	Χ
EQ-5D health status	instrument (E	Q-5D-5L) ²⁷	Χ	Χ
Questionnaires Measurin				
Mediterranean Eating	Pattern for A	Americans Questionnaire. ²⁸	Χ	Χ
BRFSS Physical Acti	vity Question	naire ²⁰	Χ	Χ
All of Us Research Prog	ram Lifestyle S	urvey (smoking/alcohol)	Χ	Χ
Exercise Self-efficacy	/ Scale ²⁹		Χ	Χ
Self-regulation Quest	tionnaire ³⁰		Χ	Χ
Physical Activity Enjo	yment Scale ³	31	Χ	Χ
Social Support for Ex	ercise Scale	(SSES). ³²	Χ	Χ
Multidimensional Out	come Expect	ations for Exercise Scale ³³	Χ	Χ
Medication History and	Cardiometabol	lic Assessments		
Medication History			Х	Χ
Zoom supervised self-a	dministered ble	ood pressure	Х	Χ
Zoom supervised self-a	dministered w	eight	Χ	Χ
Zoom guided self-admi			Х	Χ
Self-reported data duration) ³⁴	for PA inc	dex (frequency, intensity,	Х	Χ
Zoom supervised dry b	lood spot sam	ple collection for:		Χ
	•	, LDL and HDL cholesterol)	Χ	Χ
CVD risk score comp	outed using AS	SCVD Risk Calculator35	Х	Χ
Heart Health Score c	omputed usin	ng Life's Essential 8™ data	Χ	Χ
American Diabetes Association Risk Score ³⁶		Χ	Χ	
Fitbit charge 5 data on PA (continuous)		Χ	Χ	
Actigraph GT3X accelerometer data on MVPA (7 days)		Χ	Χ	
Users' Feedback		, ,		
System Usability Scale ³³	and post-inte	rvention survey		Χ

Individuals who respond to recruitment solicitations are directed to a web link that provides a brief

overview of the study and eligibility criteria. Those who are eligible are guided to follow a link to complete a battery of nine brief questionnaires which are outlined with their validation references in Table 1. For participant convenience, the questionnaires are administered via the REDCap platform so that they can be completed online in one or multiple sittings within 30 minutes. Data from the questionnaires are used for eligibility screening and will eventually allow us to examine the impact of sleep disturbance, health status, stress, and risk of depression on study outcomes. The eligibility criteria are embedded within the online surveys so that the data collection is terminated when a potential participant enters information that makes them ineligible (e.g., history of stroke). Those who complete the REDCap questionnaires and remain eligible for the study are scheduled for a 20-minute phone interview, during which the Mediterranean Eating Pattern for Americans (MEPA)²⁸ screener and the PA questionnaire ²⁰ are administered by an interviewer. Those who do not meet current PA guidelines (<150 min of MVPA/week) are scheduled for a 15-min phone call to setup the technology that they will be using in the study.

Technology set-up, informed consent, and mediation. Prior to the technology set-up phone call, we provide potential participants with email instructions on how to install Zoom (for assessments/coaching), Withings (weight, BP) and Fitbit (PA) apps. During the phone call, the study staff verify software installation and provide login credentials for the apps. Next, study staff review the study procedures and those still interested in the study receive a copy of the informed consent to review and sign via REDCap. Those who consent are asked to complete the All of Us Research Program Lifestyle Survey as well as questionnaires assessing exercise self-efficacy, 29 self-regulation, 30 PA enjoyment, 31 social support, 32 and outcome expectancy 33 (Table 1). These validated questionnaires are frequently used to identify facilitators and barriers²⁹⁻³³ that are known to influence PA and cardiovascular outcomes. 38-41 These questionnaires can be completed in REDCap within approximately 30 minutes and will be repeated at the 6-monthfollow-up visit. An optional Adverse Childhood Experiences (ACEs) questionnaire will be used to explore difficult childhood experiences that may impact variables of interest in the study. The participants will be asked by the study staff to give their verbal consent to receive this questionnaire at the end of study assessment. Baseline assessment via Zoom. Participants who meet all eligibility criteria during screening are scheduled for a baseline assessment via Zoom. Before the assessment, each participant will receive a package with all supplies including Dry Blood Spot Kit, Fitbit Charge 5, Actigraph GT3X, Withings Arm BP Monitor, Withings Scale, Perfect Waist Tape Measure, and Stretch Band. During the Zoom

visit, the study staff review the data in the PA readiness questionnaire (PAR-Q+) ²¹ to ensure that individuals who need primary care practitioner (PCP) clearance obtain it before they are randomized to the intervention or attention control condition. We use the HIPAA compliant online Fax (https://www.srfax.com) to send/receive the faxes on behalf of participants.

The assessments commence with the study staff reviewing the <u>waist circumference</u> self-measurement video and guidelines developed by the International Chair on Cardiometabolic Risk. ⁴² The staff instruct the participant to go to a private location where they can measure their waist on bare skin using the Perfect Tape Measure. The participant shows the locked tape measure to staff via the camera. There is evidence for strong correlation coefficients (0.8 to 0.9) between self- and technician-measured waist circumference using this method. ⁴³⁻⁴⁷ Next, the staff instructs the participant to wear light clothing and stand on the smart scale footpads with their bare feet to measure weight, percentage body fat, percentage body water, muscle and BMI. The study team obtains these device-recorded measures via Withings API with the PATH platform.

We use the clinically validated Withings Arm BP Monitor for self-measurement of BP. ⁴⁸ The smart monitor has a one-touch easy to read digital screen, and a cuff that fits an arm circumference of 22-42cm (larger cuffs available on request). Staff will instruct the participant to apply the cuff on the bare left arm, then sit in a chair with both feet resting flat on the floor, with back straight and supported. After 5 minutes of rest with the left arm resting on a flat surface at heart level, participants will be asked to turn on the BP machine and take 3 measurements at one-minute intervals. The study team will immediately access the device-recorded BP via Withings API with the PATH platform. Participants with 2 readings of elevated BP (>130/80 mmHg) will be referred to their PCP, with a request to update the study team if treatment is initiated. Those with severe hypertension (BP ≥180/110 mmHg) will be asked to seek urgent medical attention before their eligibility can be re-evaluated.

Blood samples for measurement of <u>HbA1C</u>, <u>adiponectin</u>, <u>LDL</u>, <u>HDL</u>, <u>and total cholesterol</u> are collected via volumetric absorptive microsampling (VAMS) approach using Mitra® dry blood spot kits. ⁴⁹ Study staff supervise participants collecting the fingerstick sample following the steps outlined in the sample collection tutorial. ⁵⁰ The samples are mailed by each participant to the lab

using the included return address. Once at the lab, the samples are stored at -80°C and will be processed at the end of study using established protocols for analysis.⁵¹

Run-in period. At the end of the baseline assessment, the staff will instruct participants to wear the Actigraph GT3X on their waist and Fitbit on their wrist to monitor PA for a 7-day run-in period. The run-in period will help potential participants appreciate study expectations and will provide objective data on baseline MVPA. Individuals will need to wear the Fitbit and Actigraph for ≥ 10 hours on ≥ 4 days to be eligible for enrollment in the study.⁵²

Randomization and orientation. After successful completion of the run-in period, non-blinded staff randomize eligible participants with equal allocation (1:1) to either the PATH intervention or the attention control arm using the REDCap randomization software. Group assignments are generated via a REDCap stratified randomization scheme to achieve a balance between the treatment and control groups regarding age (18-45; 46-64; ≥65 years), sex (male/female) and race (white/minorities). After randomization, a study staff meets with each participant on Zoom to orient them to their randomized group resources. Participants in both groups are instructed to wear Fitbit on their non-dominant hand for the entire study duration using a 24hr wear protocol, with removal only for charging.

The PATH intervention

A health coach will provide each participant with a passwordprotected profile to access the PATH website and a detailed orientation on how to use all the resources included in PATH. In addition, the health coach will meet remotely with each participant twice/month. The PATH intervention provides counsel and guidance to participants in the development of multiple behavior change strategies to promote long-term adherence to the minimum threshold of PA Guidelines (150 MVPA mins/wk). The Fitbit and Withing APIs are integrated with our PATH platform to enable near-real-time monitoring of the participant's progress. The interface also enables us to capture longitudinal trends in PA and to display the progress towards their PA goal on each participant's dashboard. The coach will work with each participant in the treatment group to develop their PA prescription guided by the FITT-VP principle⁵³ which recommends the frequency, intensity, duration, type, volume and progression of PA. Although there are no established standards on how to increase PA, available evidence suggests that it is safe to increase MVPA by 10 minutes per week.⁵⁴ Although the weekly MVPA goal translates to about 1000 steps of moderate activity/week,55 the participants are asked to target for 500 additional steps/week to make sure that the goals are safe for everyone, including those recruited with class III obesity.

The coach works with each participant to develop a tailored plan geared towards increasing MVPA by ~10 minutes per week with each coaching encounter. Given the scheduled 12 coaching encounters during the 6-month study period, participants at all levels of fitness will have a chance to develop a PA regimen that is adherent to the PA Guidelines. Participants with relatively high baseline PA are advised to target the higher threshold of the PA Guidelines (300 MVPA minutes per week). Our PA prescription process begins by identifying a suitable PATH level for each participant based on their estimated cardiorespiratory fitness level, which is estimated using a predicted maximum rate of oxygen consumption during incremental exercise (VO₂ max).⁵³ The VO₂ max is predicted using a validated, non-exercise prediction model for peak VO₂ whose covariates include sex, age, waist circumference, resting heart rate and PA index.³⁴

Individuals with predicted VO_2 max $\leq 35^{th}$ percentile for their age and gender are considered for assignment to the Beginner PATH level (includes light intensity PA [<3.0 METs]). Those with VO_2 max above 35^{th} percentile rank are assigned to Intermediate PATH level which includes moderate intensity workouts (3.0-5.9 METs) in addition to the Beginner PATH content. Based on our pilot experience, it is unlikely that a participant will be assigned to begin at the Proficient PATH level which includes vigorous intensity workout videos (\geq 6 METs). Rather, participants will be given access to the level based on their rating of perceived exertion (RPE) scores at the intermediate level and coach evaluation. The coach can change PATH level based on their assessment of the participant's capabilities during the meetings.

After assigning the PATH fitness level, the health coach guides each participant in selecting their weekly PA goal and helps them start slowly with a plan to establish regular exercise frequencies of 3-5 days/wk. The coach also guides participants to select activities with intensity to help them progress along the PA continuum (i.e., from inactive to light PA and then MVPA). To foster safety, participants are instructed to use the rating of perceived exertion (RPE) Scale⁵⁶ as a guide for adjusting the intensity of their PA regimen. The scale ranges from 6 (no exertion at all) to 20 (maximal exertion) and is embedded within each workout video on PATH. The coaches will also help participants set-up Fitbit safe heart rate zones based on their fitness levels, with a goal of progressing to the Cardio Zone (70% and 84% of maximum heart rate) by the end of the study.

Participants are asked to use workouts that elicit perceived exertion ratings between 12 to 14 (i.e., moderate intensity) on the RPE Scale. The coach reviews progress made every 2 weeks. More intensity is allowed, including transition to the next PATH level, when most workouts within the assigned PATH level are perceived to be "fairly light" (≤11 on RPE Scale). If a participant forgets to rate their workouts, their heart rate during the workout sessions is reviewed during the coaching session and a goal that aligns with each person's capabilities discussed between the health coach and




Figure 1. A Screenshot of a Participant's PATH Platform Dashboard

on ability and fitness status. Although the health coach provides

examples of workout videos that could help participants attain their personalized goals, each participant has access to all resources within their PATH level and is encouraged to select a regimen that includes their preferred workout videos and other types of PA appropriate for their fitness level. The workouts that are recommended by the health coach and those selected by each participant as favorites are featured on their PATH dashboard alongside the self-monitoring data (Figure 1).

The PA prescription is revised during the virtual meetings with the coach to reflect the progress made towards the study goal. Those who attain adherence to the PA Guidelines within the first three months will achieve the study goal and their plan for the remaining three months will be to maintain the improved PA regimen. However, each participant can opt to continue with a gradual increase in PA and/or intensity. simplify To access and maintenance of PA, the workout videos are organized into categories (e.g., walking, dance, steps aerobics) and can be sorted by duration and METs. To reduce risk of injury, the amount and intensity of PA is increased gradually, with emphasis on duration followed by intensity per the American College of Sports Medicine.⁵³ To complete PA prescription, participants are asked to suggest their preferred schedule for receiving motivational PA reminders (e.g., Remember to work out on https://pathworkouts.com today! Exercise doesn't have to leave you exhausted for it to make a difference in your health — M. Richardson). The short motivational messages are randomly selected from a bank with >270 vetted messages. Also, participants are asked to provide a schedule for the Zoom meetings with a health coach to monitor progress and revise PA goals. During the study, the participants are encouraged to share their experiences on the PATH community forum to foster community and social support. An end of study survey will capture feedback on participant experiences and the most helpful aspects of the PATH intervention resources.

The control condition

After randomization, study staff schedule a zoom meeting with each control group participant where they are guided to use their tracker and Be Active Your Way Guide.¹⁹ They also schedule a check-in meeting with them every two weeks, with the intention to keep the contact between the groups as similar as possible.

Protocols for both treatment and control arms. During the twice/month meetings with intervention and control groups, the participants receive early morning reminders to empty their bladder and step on the scale before meeting with the study staff who supervise BP measurements on Zoom. These data are used to monitor trends in BP, weight, and body composition during the study period. Both the intervention and control arms receive an email with a brief PDF addressing one diet component every 4 weeks. The diet information is also available to them as modules on the PATH platform (control group access on PATH is limited to the nutritional resources). At the end of the 6-month study assessments, both control and intervention group participants are given the option to continue using the PATH platform at their convenience without any interaction with the coaches.

Study outcomes

Indicators of PATH Fresher algorithm's effectiveness in identifying workouts that match user preferences. Effectiveness of the PATH Fresher algorithm will be indicated by its ability to analyze PATH users' data, spin up new browser sessions in the background to activate the YouTube recommender system and select new workouts like those highly rated ($\geq 3.5/5$ stars) by study users. At the end of the study, the coaches will vet the new workouts recommended by the PATH Fresher algorithm. The acceptance of $\geq 50\%$ of the top twenty recommended workouts for inclusion in PATH will indicate the effectiveness of PATH Fresher algorithm. The Systems Usability survey (SUS)³⁷ will be completed by participants to evaluate overall satisfaction with the PATH platform.

Acceptability of the disseminated educational resources focusing on improving diet quality. The resources will be curated from an extensive library of standard behavioral treatment (SBT) content previously developed and validated by the SMARTER study team. ^{57,58} Their acceptability will be indicated by 70% of the participants rating the materials as helpful via a researcher-developed end-of-study survey (see appendix I).

Measures of PA and adherence to PA guidelines. The efficacy of PATH in enhancing adherence to PA Guidelines will be evaluated at 6 months using MVPA data collected via ActiGraph GT3X, ⁵⁹ worn on the waist for 7 days at 6 months. Adherence to PA Guidelines will be defined as achieving ≥150 min of MVPA/wk. Percent change in adherence will be calculated as: [(Post-intervention MVPA - Baseline

MVPA)/Recommended MVPA×100]. Between group difference in % change in adherence and proportion of individuals who attain the recommended MVPA will be evaluated. Established and novel methods will be used to process ActiGraph data which will be considered valid if ≥4 days with ≥10hrs of wear time are measured.⁵⁹ Actigraph non-wear time was defined using the Choi wear time validation algorithm.⁶⁰ Fitbit valid data was indicated by ≥4 days with ≥500 steps/day as recommended by Thorndike et al.⁶¹ and other studies.⁶² Sustained PA engagement will be evaluated via Active Minutes data collected via Fitbit Charge 5 and will be analyzed via the adherence strategy described above. Validation studies suggest that Fitbit is ideally suited for long-term self-monitoring of PA due to its user friendliness and extensive use in RCTs.⁶³

Measures of cardiovascular outcomes. <u>Cardiovascular outcomes</u> will be indicated by change from baseline to end of 6-month study post-intervention in CVD risk score calculated using the 2013 Atherosclerotic Cardiovascular Disease (ASCVD) Risk Calculator. ⁶⁴ The algorithm provides sex and race-specific estimates for the first CVD events. The scores range from 0-100% with higher scores representing poor cardiovascular health status. The composite risk factors included in the algorithm are age, total and HDL cholesterol, SBP (including treated/untreated status), diabetes, and current smoking status. These will be measured using the protocols outlined under baseline assessment. The main outcome will be between group difference in risk score change from baseline. We will employ the same strategy to evaluate changes in independent risk factors for CVD (secondary outcomes): waist circumference, weight, BP, Life's Essential 8[™], HbA1C, adiponectin, and lipids (total, LDL, HDL cholesterol).

Sample Size Justification. Given our repeated measures study design, we anticipate some participant attrition. To ensure sufficient sample size with complete assessment through 6-months follow-up, we plan to enroll 88 participants (44 per treatment group) retaining at least 76 participants (38 per treatment group) assuming a 14% attrition through the 6-month follow-up based on attrition rates observed in the literature. When estimating within-group changes to describe the effect of PATH on study outcomes using either proportions or means, with at least 38 participants per treatment group (76 total), we would have at least 80% power to detect small-to-medium effect sizes for the efficacy of the PATH intervention. For PA, this corresponds to a mean difference of 20 mins of MVPA or 13.3% absolute change in terms of adherence to PA guidelines. For CVD risk factors, linear contrasts from either linear or generalized linear mixed modeling will be specified and estimated to compare the treatment groups on the 6-month change in CVD risk scores and risk factors at testwise (Bonferoni-adjusted) significance level of .05.

Statistical Analysis. Data will be analyzed using SAS Version 9.4 (SAS Institute, Inc., Cary, NC) to conduct exploratory data analyses for data screening, including missing data assessment, as well as repeated measures modeling, and modeling of attrition. Mplus (version 8.8, Muthén & Muthén, Los Angeles, CA) will be used for mediational analyses to explore possible mechanisms of action of the PATH intervention. Data will first be carefully screened with the results of these preliminary analyses informing the final analysis strategies to be applied to address study aims and exploratory analyses. Although hypotheses are stated as directional, hypothesis testing will be non-directional with the significance level set to 0.05 and confidence interval estimation at 95%. The randomness of missing data will be investigated using information on participant characteristics to help discern patterns in the missing data, identify possible missing data mechanisms, and inform strategies to handle missing data. If data are not missing at random, we will apply multiple imputation and two extreme case scenarios (worst/best case) to address missing data. If nonrandom missingness is suspected, we will use selection or pattern mixture modeling to explore the sensitivity of results to the assumed missing data patterns.

An intent-to-treat (ITT) approach will be used to test the efficacy of the PATH intervention on the distal outcome of adherence to the PA guidelines over time. Since key study endpoints are assessed at multiple time points, repeated measures modeling (e.g., linear or generalized linear mixed modeling methods and/or marginal modeling using generalized estimating equations as appropriate, both assuming a normal error structure) will be used to test the efficacy of the PATH intervention on the measures of adherence to the PA guidelines over time (baseline [0], and 6-months [long-term] follow-up). To test the hypothesis that the PATH intervention group will have greater adherence to PA guidelines compared to the attention control group, linear contrasts will be specified and estimated to compare adherence to PA guidelines between the treatment groups at 6 months relative to baseline values, respectively. The testwise significance level will be set to 0.05 (Bonferroniadjusted). Point and interval (95% confidence intervals) estimates based on linear contrasts will also be computed as both unstandardized and standardized effect sizes of the efficacy of the PATH intervention.

Analysis strategy to compare the effects of the PATH intervention on CVD risk factors. A similar repeated measures modeling approach as outlined above will be utilized to evaluate the efficacy of the PATH intervention compared to the attention control condition on CVD risk factors including CVD risk score, weight, blood pressure, waist circumference, HbA1C, and lipids at 6-months follow-up. These measures of CVD risk are either interval or ratio scaled, and a normal error structure (or following a suitable data transformation) will be assumed when modeling. As necessary,

generalized linear mixed modeling assuming a binomial error will be applied to model CVD risk factors dichotomized based on clinically meaningful cut points. To test the hypothesis that the PATH intervention group will have a greater reduction in CVD risk score vs. the control group, linear contrasts will be specified and estimated to compare the treatment groups on the change in CVD risk scores at 6-months follow-up relative to baseline values at a testwise significance level of 0.05 and confidence interval estimation at 95%.

Data Management and Confidentiality

All technologies to be used in this study, including AWS webhosting platform, PATH website, Twilio, SR Fax, Actigraph, Fitbit, and Withings apps were reviewed and approved by Emory University's Enterprise Information Security Team. The entire data collection infrastructure, including the REDCap and PATH platforms, were tested by the study team before it was deployed for data collection. Confidentiality will be ensured by use of a simple identification number (ID), meaning it will not be encoded to denote other variables. Data will be stored on a password protected computer with access limited to the staff who monitor participants' adherence and safety, and the data management team. Access to the master list of participant names and ID numbers will be limited to the staff who conduct the screening and intervention procedures as they need to interact with these individuals on a name basis. The staff who do not interact with participants are blinded to name and treatment assignment.

Plans to Monitor the Data to Ensure Safety of Participants and Data Integrity

A data safety and monitoring plan will be implemented to ensure the safety of all participants involved in the study and to ensure the validity and integrity of the collected data. The PI and biostatistician (in conjunction with the project coordinators and staff), will be responsible for execution of this plan under the oversight of a safety officer and the IRB. The safety officer will act in an advisory capacity to the PI and the NIH program director.

Discussion

The significance of addressing physical inactivity in adults with obesity cannot be overstated. The PATH intervention is testing a novel strategy for addressing the multifaceted barriers to PA among adults with obesity. Our study protocol is grounded in the understanding that traditional PA programs often fail to engage this population because they do not address their unique barriers to PA including stigma, poor fitness, low self-efficacy, unmet weight loss expectations and limited access to relatable

exercise programs.^{66,67} By engaging users via tailored workout videos, virtual coaching, and digital self-monitoring tools, the PATH intervention offers a scalable, participant-centered, and highly accessible solution to address barriers to PA engagement among individuals with obesity. The weight neutral messaging included in PATH programming is intentionally designed to help participants focus on getting active without being discouraged by limited weight loss progress.

Preliminary evidence from formative studies suggests that the PATH intervention is promising in promoting PA engagement and adherence among adults with obesity. ¹⁸ The integration of personalized virtual coaching with a highly accessible and user-friendly web-based platform addresses key limitations of previous web-based and mHealth PA interventions, which often lacked the individualized support necessary to sustain long-term behavior change. ⁶⁷⁻⁶⁹ Our approach in this RCT aligns with recent studies that have highlighted the importance of combining technology with human interaction to promote engagement and adherence in PA programs. ^{18,69} Moreover, the use of validated smart digital tools (e.g., Fitbit tracker, Withings scale and BP monitor) that are interfaced with the user-facing dashboard on PATH facilitates near real-time accurate monitoring of multiple cardiovascular health indicators without increasing participant burden. These tools enable the coaches to offer timely feedback and appropriate support during virtual coaching sessions, helping the participants maintain PA engagement over time.

If successful in promoting PA adherence, the PATH intervention could provide a practical, scalable option that healthcare providers can recommend to patients who struggle with PA adherence, especially those with obesity. Because PA has been shown to reduce the risk of CVD even without weight loss, 70 the PATH intervention has the potential to play a critical role in improving health outcomes in this high-risk population. The program's weight neutral messaging encourages the participants to focus on being active with a goal of achieving cardiovascular health benefits, even if no weight loss is attained. This careful messaging is intended to mitigate unmet weight loss expectations which are a major impediment to long-term adherence to PA in this high-risk population. 71

Understanding the mechanisms of action underlying the efficacy of PATH is highly significant. In this study, we are examining factors such as self-efficacy, social support, and outcome expectations to gain more insights into how the PATH intervention facilitates behavior change. These data will inform further refinement and optimization of the PATH platform. The next phase of optimization could leverage novel digital health technologies such as artificial intelligence (AI) for enhanced personalization to further improve the engagement and efficacy of the PATH intervention. This presents a promising opportunity for providing a more tailored and engaging experience for users,

which aligns with the growing trend of technology-enhanced preventive health solutions.

This study has a few limitations that are worth acknowledging. The relatively small sample size may limit the generalizability of findings, and our eligibility criteria may favor participants with higher levels of digital literacy and access to technology. Future research should focus on addressing these limitations by conducting larger-scale trials that evaluate long-term efficacy and sustainability of PA adherence, with proactive strategies to reach populations with limited digital access. After large-scale efficacy trials, comparative effectiveness studies may be needed to determine how PATH performs relative to other web-based, in-person, or hybrid PA interventions to identify the most effective strategies for promoting PA adherence in adults with obesity. Additionally, evaluating the costeffectiveness of PATH compared to traditional PA programs or other web-based/mHealth interventions is also necessary to examine its value as a sustainable solution in real-world settings. Moreover, future research should explore how the PATH platform can be further tailored to meet the needs of specific subgroups, such as older adults, individuals from diverse cultural backgrounds, or those with comorbidities like diabetes or hypertension. This will enhance the intervention's relevance and effectiveness for a broader range of individuals. Then, future studies can explore how the PATH intervention can be availed to healthcare systems to facilitate seamless referral of sedentary high-risk patients by clinicians, making PATH a more practical tool for promoting PA in routine clinical practice. Currently, there are very few options for structured PA programs that healthcare providers can refer their patients to beyond physical therapy.

Conclusion

In conclusion, the PATH intervention offers a promising, evidence-based approach to overcoming the barriers that have hindered previous PA programs for adults with obesity. For instance, most of the existing supervised PA programs, such as cardiac rehabilitation are usually short-term and address recovery to a baseline – rather than long-term maintenance of health-enhancing PA. By incorporating user preferences, human support, and a flexible, scalable web-based platform, the PATH intervention is poised to significantly improve PA adherence and reduce the risk of CVD in this high-risk population. If the PATH program proves to be efficacious in promoting PA among individuals with obesity, it could be an option for referral at the end of cardiac rehabilitation to promote and maintain a regular PA regimen. The findings from this RCT will contribute valuable insights to the field of research focusing on behavioral interventions to manage obesity, with potential implications for reducing the burden of obesity-related diseases. This aligns with the broader goal of preventive healthcare models that emphasize lifestyle modification as a cornerstone for managing chronic diseases.^{71,72}

References

1. Office of Disease Prevention and Health Promotion; Nutrition, Physical Activity, and Obesity | Healthy People 2020. health.gov.

- 2. Bennie JA, De Cocker K, Teychenne MJ, Brown WJ, Biddle SJH. The epidemiology of aerobic physical activity and muscle-strengthening activity guideline adherence among 383,928 U.S. adults. *International Journal of Behavioral Nutrition and Physical Activity 2019 16:1*. 2019;16(1):1-11. doi:10.1186/S12966-019-0797-2
- 3. U.S. Department of Health and Human Services. *Physical Activity Guidelines for Americans.*; 2018.
- 4. Kraus WE, Bittner V, Appel L, et al. The National Physical Activity Plan: a call to action from the American Heart Association: a science advisory from the American Heart Association. *Circulation*. 2015;131(21):1932-1940. doi:10.1161/CIR.00000000000000203 [doi]
- 5. FW B, SJ L. Fundamental questions about genes, inactivity, and chronic diseases. *Physiol Genomics*. 2007;28(2):146-157. doi:10.1152/PHYSIOLGENOMICS.00174.2006
- 6. Jeon CY, Lokken RP, Hu FB, Van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: A systematic review. *Diabetes Care*. 2007;30(3):744-752. doi:10.2337/dc06-1842
- 7. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: A report of the American College of cardiology/American Heart Association task force on practice guidelines and the obesity society. *Circulation*. 2014;129(25 SUPPL. 1):S102-S138. doi:10.1161/01.cir.0000437739.71477.ee
- 8. Martinez-Gomez D, Lavie CJ, Hamer M, et al. Physical activity without weight loss reduces the development of cardiovascular disease risk factors a prospective cohort study of more than one hundred thousand adults. *Prog Cardiovasc Dis.* 2019;62(6):522-530. doi:10.1016/J.PCAD.2019.11.010
- 9. Bombak AE. Obese persons' physical activity experiences and motivations across weight changes: a qualitative exploratory study. *BMC Public Health*. 2015;15(1):1129. doi:10.1186/s12889-015-2456-0
- 10. Mcintosh T, Hunter DJ, Royce S. Barriers to physical activity in obese adults: A rapid evidence assessment. *UK Journal of Research in Nursing*. 2016;21(4):271-287. doi:10.1177/1744987116647762
- 11. Schvey NA, Sbrocco T, Bakalar JL, et al. The Experience of Weight Stigma Among Gym Members With Overweight and Obesity. *Association*. 2017;2(4):292-306. doi:10.1037/sah0000062
- 12. Ekkekakis P, Vazou S, Bixby WR, Georgiadis E. The mysterious case of the public health guideline that is (almost) entirely ignored: Call for a research agenda on the causes of the extreme avoidance of physical activity in obesity. *Obesity Reviews*. 2016;17(4):313-329. doi:10.1111/obr.12369
- 13. Lip GYH, Al-Khatib SM, Cosi FG, et al. Contemporary management of atrial fibrillation: What can clinical registries tell us about stroke prevention and current therapeutic approaches? *J Am Heart Assoc.* 2014;3(4). doi:10.1161/JAHA.114.001179
- 14. Cajita MI, Zheng Y, Kariuki JK, Vuckovic KM, Burke LE. mHealth Technology and CVD Risk Reduction. *Curr Atheroscler Rep.* 2021;23(7). doi:10.1007/s11883-021-00927-2
- 15. Kariuki JK, Gibbs BB, Davis KK, Mecca LP, Hayman LL, Burke LE. Recommendations for a

- Culturally Salient Web-based Physical Activity Program for African Americans. *Transl J Am Coll Sports Med.* 2019;4(2):8-15.
- 16. Joseph RP, Durant NH, Benitez TJ, Pekmezi DW. Internet-Based Physical Activity Interventions. *Am J Lifestyle Med*. 2014;8(1):42-67. doi:10.1177/1559827613498059
- 17. Hills AP, Byrne NM. State of the Science: A Focus on Physical Activity. Vol 15.; 2006.
- 18. Kariuki JK, Sereika S, Erickson K, et al. Feasibility and preliminary efficacy of a novel webbased physical activity intervention in adults with overweight/obesity: A pilot randomized controlled trial. *Contemp Clin Trials*. 2023;133. doi:10.1016/J.CCT.2023.107318
- 19. United States. Department of Health and Human Services. Be active your way: a guide for adults: based on the 2008 physical activity guidelines for Americans: be active, healthy, and happy!. Published online 2008:22.
- 20. Yore MM, Ham SA, Ainsworth BE, et al. Reliability and validity of the instrument used in BRFSS to assess physical activity. *Med Sci Sports Exerc*. 2007;39(8):1267-1274. doi:10.1249/MSS.0B013E3180618BBE
- 21. PAR-Q+ Collaboration. The New PAR-Q+ physical activity and exercise participation for everyone! www.eparmedx.com. 2021. Accessed June 20, 2022. https://eparmedx.com/
- 22. Paffenbarger RS, Wing AL, Hyde RT. Physical activity as an index of heart attack risk in college alumni. *Am J Epidemiol*. 1978;108(3):161-175. Accessed January 30, 2018. http://www.ncbi.nlm.nih.gov/pubmed/707484
- 23. McAuley E. The role of efficacy cognitions in the prediction of exercise behavior in middle-aged adults. *J Behav Med.* 1992;15(1):65-88. doi:10.1007/BF00848378
- 24. Yu L, Buysse DJ, Germain A, et al. Development of Short Forms From the PROMIS[™] Sleep Disturbance and Sleep-Related Impairment Item Banks. *Behavioral Sleep Medicine*. 2011;10(1):6-24. doi:10.1080/15402002.2012.636266
- 25. Van Dam NT, Earleywine M. Validation of the Center for Epidemiologic Studies Depression Scale-Revised (CESD-R): Pragmatic depression assessment in the general population. *Psychiatry Res.* 2011;186:128-132. doi:10.1016/j.psychres.2010.08.018
- 26. Salsman JM, Butt Z, Pilkonis PA, et al. Emotion assessment using the NIH Toolbox. *Neurology*. 2013;80(11 Suppl 3):S76. doi:10.1212/wnl.0b013e3182872e11
- 27. Balestroni G, Bertolotti G. EuroQol-5D (EQ-5D): An instrument for measuring quality of life. *Monaldi Archives for Chest Disease Cardiac Series*. 2012;78(3):155-159. doi:10.4081/monaldi.2012.121
- 28. Cerwinske LA, Rasmussen HE, Lipson S, Volgman AS, Tangney CC. Evaluation of a dietary screener: the Mediterranean Eating Pattern for Americans tool. *J Hum Nutr Diet*. 2017;30(5):596-603. doi:10.1111/JHN.12451
- 29. Neupert SD, Lachman ME, Whitbourne SB. Exercise Self-Efficacy and Control Beliefs Predict Exercise Behavior After an Exercise Intervention for Older Adults NIH Public Access. *J Aging Phys Act*. 2009;17(1):1-16.
- 30. Rovniak LS, Anderson ES, Winett RA, Stephens RS. Social cognitive determinants of physical activity in young adults: A prospective structural equation analysis. *Annals of Behavioral Medicine*. 2002;24(2):149-156. doi:10.1207/S15324796ABM2402_12
- 31. Kendzierski D, DeCarlo KJ. Physical Activity Enjoyment Scale: Two Validation Studies. *J Sport Exerc Psychol.* 1991;13(1):50-64. doi:10.1123/JSEP.13.1.50
- 32. Sallis JF, Grossman RM, Pinski RB, Patterson TL, Nader PR. The development of scales to measure social support for diet and exercise behaviors. *Prev Med (Baltim)*. 1987;16(6):825-836. doi:10.1016/0091-7435(87)90022-3

33. Wójcicki TR, White SM, McAuley E. Assessing Outcome Expectations in Older Adults: The Multidimensional Outcome Expectations for Exercise Scale. *J Gerontol B Psychol Sci Soc Sci*. 2009;64B(1):33. doi:10.1093/GERONB/GBN032

- 34. Nes BM, Janszky I, Vatten LJ, Nilsen TIL, Aspenes ST, WislØff U. Estimating VO2peak from a nonexercise prediction model: The HUNT study, Norway. *Med Sci Sports Exerc*. 2011;43(11):2024-2030. doi:10.1249/MSS.0b013e31821d3f6f
- 35. Goff DC, Lloyd-jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49-73. doi:10.1161/01.cir.0000437741.48606.98 [doi]
- 36. Heikes KE, Eddy DM, Arondekar B, Schlessinger L. Diabetes Risk Calculator: a simple tool for detecting undiagnosed diabetes and pre-diabetes. *Diabetes Care*. 2008;31(5):1040-1045. doi:10.2337/dc07-1150
- 37. Hyzy M, Bond R, Mulvenna M, et al. System Usability Scale Benchmarking for Digital Health Apps: Meta-analysis. *JMIR Mhealth Uhealth*. 2022;10(8):e37290. doi:10.2196/37290
- 38. Conroy MB, Yang K, Elci OU, et al. Physical activity self-monitoring and weight loss: 6-month results of the SMART trial. *Med Sci Sports Exerc*. 2011;43(8):1568-1574. doi:10.1249/MSS.0b013e31820b9395
- 39. Acharya SD, Elci OU, Sereika SM, et al. Adherence to a behavioral weight loss treatment program enhances weight loss and improvements in biomarkers. *Patient Prefer Adherence*. 2009;3:151. doi:10.2147/PPA.S5802
- 40. Zheng Y, Terhorst L, Choo J, Burke LE. Psychometric properties of the perceived therapeutic efficacy scale for adhering to a cholesterol-lowering diet. *Journal of Cardiovascular Nursing*. 2014;29(3):257-263. doi:10.1097/JCN.0b013e31828f910f
- 41. Burke LE, Ewing LJ, Ye L, et al. The SELF trial: A self-efficacy-based behavioral intervention trial for weight loss maintenance. *Obesity*. 2015;23(11):2175-2182. doi:10.1002/oby.21238
- 42. International Chair on Cardiometabolic Risk. Waist Circumference Measurement Guidelines. myhealthywaist.org. 2011. Accessed November 9, 2020. http://www.myhealthywaist.org/index.php?id=90
- 43. Pendergast K, Wolf A, Sherrill B, et al. Impact of waist circumference difference on health-care cost among overweight and obese subjects: the PROCEED cohort. *Value Health*. 2010;13(4):402-410. doi:10.1111/j.1524-4733.2009.00690.x
- 44. EA S, AW R, TJ K. Accuracy of self-reported waist and hip measurements in 4492 EPIC-Oxford participants. *Public Health Nutr.* 2004;7(6):723-727. doi:10.1079/PHN2004600
- 45. CA R, LB W, RT J, TF M, DM B. Accuracy of self-measurement of waist and hip circumference in men and women. *J Am Diet Assoc*. 1997;97(5):534-536. doi:10.1016/S0002-8223(97)00137-5
- 46. Bigaard J, Spanggaard I, Thomsen BL, Overvad K, Tjønneland A. Self-reported and technician-measured waist circumferences differ in middle-aged men and women. *J Nutr*. 2005;135(9):2263-2270. doi:10.1093/jn/135.9.2263
- 47. Ross R, Neeland IJ, Yamashita S, et al. Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity. *Nat Rev Endocrinol*. 2020;16(3):177-189. doi:10.1038/s41574-019-0310-7
- 48. Brickwood KJ, Watson G, O'brien J, Williams AD. Consumer-Based Wearable Activity Trackers Increase Physical Activity Participation: Systematic Review and Meta-Analysis. *JMIR Mhealth Uhealth*. 2019;7(4). doi:10.2196/11819
- 49. Marchand A, Roulland I, Semence F, Audran M. Volumetric Absorptive Microsampling (VAMS)

- technology for IGF-1 quantification by automated chemiluminescent immunoassay in dried blood. *Growth Horm IGF Res.* 2020;50:27-34. doi:10.1016/J.GHIR.2019.12.001
- 50. Protti M, Mandrioli R, Mercolini L. Tutorial: Volumetric absorptive microsampling (VAMS). *Anal Chim Acta*. 2019;1046:32-47. doi:10.1016/j.aca.2018.09.004
- 51. Verougstraete N, Stove V, Stove CP. Remote HbA1c testing via microsampling: fit for purpose? *Clin Chem Lab Med.* 2023;62(1):3-17. doi:10.1515/CCLM-2023-0228
- 52. Hwang J, Fernandez AM, Lu AS. Application and Validation of Activity Monitors' Epoch Lengths and Placement Sites for Physical Activity Assessment in Exergaming. *J Clin Med*. 2018;7(9). doi:10.3390/jcm7090268
- 53. Dalleck LC, Tischendorf JS. *Guidelines for Exercise Testing and Prescription (ACSM).*; 2012. doi:10.4135/9781412994149.n165
- 54. Office of Disease Prevention and Health Promotion. Physical Activity Guidelines: Safe and Active. Health.gov. 2018. Accessed January 27, 2018. https://health.gov/paguidelines/guidelines/chapter6.aspx
- 55. Slaght J, Sénéchal M, Hrubeniuk TJ, Mayo A, Bouchard DR. Walking Cadence to Exercise at Moderate Intensity for Adults: A Systematic Review. *Journal of Sports Medicine*. 2017;2017:1-12. doi:10.1155/2017/4641203
- 56. Borg G. *An Introduction to Borg's RPE-Scale*. Mouvement Publications; 1985. Accessed September 12, 2017. http://www.worldcat.org/title/introduction-to-borgs-rpe-scale/oclc/13790520?referer=di&ht=edition
- 57. Burke LE, Zheng Y, Ma Q, et al. The SMARTER pilot study: Testing feasibility of real-time feedback for dietary self-monitoring. Published online 2017. doi:10.1016/j.pmedr.2017.03.017
- 58. Burke LE, Sereika SM, Bizhanova Z, et al. The Effect of Tailored, Daily, Smartphone Feedback to Lifestyle Self-Monitoring on Weight Loss at 12 Months: the SMARTER Randomized Clinical Trial. *J Med Internet Res.* 2022;24(7). doi:10.2196/38243
- 59. Sasaki JE, John D, Freedson PS. Validation and comparison of ActiGraph activity monitors. *J Sci Med Sport*. 2011;14(5):411-416. doi:10.1016/J.JSAMS.2011.04.003
- 60. Choi L, Liu Z, Matthews CE, Buchowski MS. Validation of accelerometer wear and nonwear time classification algorithm. *Med Sci Sports Exerc*. 2011;43(2):357-364. doi:10.1249/MSS.0b013e3181ed61a3
- 61. Thorndike AN, Mills S, Sonnenberg L, et al. Activity monitor intervention to promote physical activity of physicians-in-training: randomized controlled trial. *PLoS One*. 2014;9(6). doi:10.1371/JOURNAL.PONE.0100251
- 62. Bizhanova Z, Sereika SM, Brooks MM, Rockette-Wagner B, Kariuki JK, Burke LE. Identifying Predictors of Adherence to the Physical Activity Goal: A Secondary Analysis of the SMARTER Weight Loss Trial. *Med Sci Sports Exerc*. Published online 2022. https://journals.lww.com/acsmmsse/Fulltext/9900/Identifying Predictors of Adherence to the 190.aspx
- 63. Fitbit. Fitabase Research Library. 2021. Accessed August 25, 2021. https://www.fitabase.com/research-library/#:~:text=The following 761 publications have,study not on our list%3F
- 64. Goff DC, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;129(25 Suppl 2):S49-73. doi:10.1161/01.cir.0000437741.48606.98 [doi]
- 65. Gill DP, Blunt W, Silva NCBS, Stiller-Moldovan C, Zou GY, Petrella RJ. The Health e Steps ™ lifestyle prescription program to improve physical activity and modifiable risk factors for chronic

- disease: a pragmatic randomized controlled trial. *BMC Public Health 2019 19:1*. 2019;19(1):1-15. doi:10.1186/S12889-019-7141-2
- 66. Kariuki JK, Gibbs BB, Davis KK, Mecca LP, Hayman LL, Burke LE. Recommendations for a Culturally Salient Web-Based Physical Activity Program for African Americans. *Transl J Am Coll Sports Med.* 2019;4(2).
- 67. Mcintosh T, Hunter DJ, Royce S. Barriers to physical activity in obese adults: A rapid evidence assessment. *UK Journal of Research in Nursing*. 2016;21(4):271-287. doi:10.1177/1744987116647762
- 68. Joseph RP, Durant NH, Benitez TJ, Pekmezi DW. Internet-Based Physical Activity Interventions. http://dx.doi.org/101177/1559827613498059. 2013;8(1):42-67. doi:10.1177/1559827613498059
- 69. Cajita MI, Zheng Y, Kariuki JK, Vuckovic KM, Burke LE. mHealth Technology and CVD Risk Reduction. *Curr Atheroscler Rep.* 2021;23(7). doi:10.1007/S11883-021-00927-2
- 70. Martinez-Gomez D, Lavie CJ, Hamer M, et al. Physical activity without weight loss reduces the development of cardiovascular disease risk factors a prospective cohort study of more than one hundred thousand adults. *Prog Cardiovasc Dis.* 2019;62(6):522-530. doi:10.1016/J.PCAD.2019.11.010
- 71. Ekkekakis P, Vazou S, Bixby WR, Georgiadis E. The mysterious case of the public health guideline that is (almost) entirely ignored: Call for a research agenda on the causes of the extreme avoidance of physical activity in obesity. *Obesity Reviews*. 2016;17(4):313-329. doi:10.1111/obr.12369
- 72. Kariuki JK, Imes CC, Engberg SJ, Scott PW, Klem ML, Cortes YI. Impact of lifestyle-based interventions on absolute cardiovascular disease risk: a systematic review and meta-analysis. *JBI Evid Synth*. Published online August 7, 2023. doi:10.11124/JBIES-22-00356

Supplementary Files

Multimedia Appendixes

NIH Review.

URL: http://asset.jmir.pub/assets/9a8a2fd55f3a5053d6e483fc7e390577.pdf